Scilex Holding to Go Public Through Merger with Singapore-Based SPAC
January 29, 2023
Trending News 🌥️
Scilex ($NASDAQ:SCLX) focuses on developing and marketing non-opioid treatments for people with chronic and acute pain. SPACs are also known as “blank check” companies because they raise money through an Initial Public Offering (IPO) and then either purchase or merge with a private company to enable it to go public. Scilex has several product candidates in its pipeline, including ZTlido, which is approved by the U.S. Food and Drug Administration (FDA) as a lidocaine topical system for the relief of pain associated with post-herpetic neuralgia. The proposed merger will provide the necessary capital to enable Scilex to advance its pipeline and support further development of its products.
The proposed merger between Scilex and Vickers Vantage Corp I is expected to be beneficial for all stakeholders involved. The merger will provide Scilex with the capital it needs to continue to develop and commercialize its non-opioid treatments and will also provide investors with an opportunity to invest in the healthcare sector with a focus on non-opioid pain management.
Market Price
On Tuesday, news broke that Scilex Holding, a privately held pharmaceutical company, is going public through a merger with a Singapore-based Special Purpose Acquisition Company (SPAC). Although news sentiment was mostly positive, the stock opened at $9.6 and closed at $6.5, a 31.3% plunge from its last closing price of 9.5. This allows the company to benefit from increased liquidity and access to capital, while providing potential investors with an opportunity to invest in the company. The merger should also help Scilex Holding expand its portfolio of products, as well as its distribution channels. Furthermore, the company will be able to use the proceeds to fund research and development of new products, as well as accelerate its growth in the international market.
After the merger is completed, Scilex Holding’s common shares will be listed on the Nasdaq Global Market under a new ticker symbol. This news marks an important milestone for Scilex Holding, as it prepares to become a publicly traded company. This will provide the company with the resources and flexibility to pursue its growth strategy and become a major player in the pharmaceutical industry. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Scilex Holding. More…
| Total Revenues | Net Income | Net Margin |
| – | – | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Scilex Holding. More…
| Operations | Investing | Financing |
| – | – | – |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Scilex Holding. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| – | – | – |
Key Ratios Snapshot
Some of the financial key ratios for Scilex Holding are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| – | – | – |
| FCF Margin | ROE | ROA |
| – | – | – |
VI Analysis
SCILEX HOLDING is a medium risk investment according to VI Risk Rating, which evaluates the company’s fundamentals to determine its long term potential. The rating takes into account both financial and business aspects. However, the VI App has detected 2 risk warnings in the company’s balance sheet and financial journal, which may affect its ability to perform as expected in the future. The company’s balance sheet and financial journal are important indicators of its long-term financial stability and performance. They provide insight into the company’s liquidity, debt, assets, and other financial measures. By analyzing these documents, investors can get a better understanding of the company’s financial position and potential risks. In addition to the risk warnings highlighted by the VI App, investors should also consider other factors such as the company’s competitive position in the market, its management team, and its track record of profitability. Additionally, investors should evaluate the company’s dividend policy, as well as its share price and dividends paid out over time. Overall, SCILEX HOLDING is a medium risk investment according to VI Risk Rating. Investors should take note of the risk warnings identified by the VI App and consider all available information before making their final decision. Becoming a registered user of the VI App allows investors to access more detailed analysis and insights. More…
VI Peers
The competition between Scilex Holding Co and its competitors, Laxai Pharma Ltd, Nordic Nanovector ASA, and Scholar Rock Holding Corp, is fierce in the pharmaceutical industry. All four companies are vying for market share as they strive to provide the best products and services to their customers. Each of these companies brings a unique set of offerings to the market, and their competition is driving innovation and growth.
– Laxai Pharma Ltd ($OTCPK:LAXAF)
Laxai Pharma Ltd is a pharmaceutical company that specializes in the manufacturing and distribution of generic drugs. The company has a market capitalization of 475.34k as of 2023, which makes it one of the smaller players in the pharmaceutical industry. Its return on equity (ROE) is 15.34%, which indicates that the company is doing well financially. The company has a strong balance sheet and is well-positioned to take advantage of opportunities in the industry. The company is committed to providing quality generic drugs to consumers at an affordable price.
– Nordic Nanovector ASA ($LTS:0R6Y)
Nordic Nanovector ASA is a biopharmaceutical company focused on developing and commercializing novel targeted therapeutics for cancer. The company has a market cap of 117.89M as of 2023 and a Return on Equity of -119.17%. This suggests that the company is not performing well financially, indicating that investors may be less inclined to buy shares in the company. The negative return on equity is likely due to increased costs associated with the development of new products and the high cost of research and development. Despite the lack of strong financials, Nordic Nanovector is still considered an innovative company in the biopharmaceutical industry, with potential for growth in the future.
– Scholar Rock Holding Corp ($NASDAQ:SRRK)
Scholar Rock Holding Corp is a biopharmaceutical company that develops and commercializes novel biologic therapies for the treatment of serious diseases. The company has a market cap of 654.06 million as of 2023, indicating the value of its outstanding shares in the market. In addition, the company has a Return on Equity (ROE) of -25.95%, which shows that it is not generating enough profit to cover its equity investments. This means that the company is not utilizing its resources efficiently and is underperforming its peers.
Summary
Scilex Holding, a Singapore-based company, recently announced its plans to go public through a merger with a Singapore-based Special Purpose Acquisition Company (SPAC). The news has been mostly positive, with market sentiment towards the company being generally optimistic. Despite this, the stock price of the company dropped on the same day the announcement was made. Investors should take this into consideration when analyzing the potential of Scilex Holding as an investment opportunity.
They should also consider any additional information available on the company, such as financials and industry trends, in order to make an informed decision. Ultimately, the success of any investment in Scilex Holding will depend on the investor’s ability to accurately assess the risk and potential rewards involved.
Related Posts
Recent Posts
